Potential Breakthroughs in Neurotherapeutics: Alzheimer’s Disease, Parkinson’s Disease, Depression, Bipolar Disorder, and Schizophrenia : Market Research Report

Potential Breakthroughs in Neurotherapeutics: Alzheimer’s Disease, Parkinson’s Disease, Depression, Bipolar Disorder, and Schizophrenia

Published by: CHI Insight Pharma Reports

Published: Oct. 1, 2006 - 198 Pages

CHAPTER 1 INTRODUCTION: NEUROLOGICAL DISORDERS HAVE CLEAR UNMET NEEDS: 1.1. Clarifying the Problems; 1.2. Translating the Research
CHAPTER 2 CURRENT STATUS AND TRENDS IN TECHNOLOGY TRANSFER: 2.1. The Nature of Technology Transfer Today; 2.2. Effects of Government Policy on Technology Transfer; 2.3. Problems Surrounding Technology Transfer; 2.4. Translational Medicine Comes to Academia
CHAPTER 3 BACKGROUND INFORMATION ON DISEASES TARGETED FOR THIS REPORT: 3.1. Alzheimer¡¯s Disease; 3.2. Parkinson¡¯s Disease; 3.3. Unipolar Depression; 3.4. Bipolar Disorder; 3.5. Schizophrenia
CHAPTER 4 CURRENT BASIC RESEARCH FINDINGS WITH HIGH POTENTIAL FOR COMMERCIAL APPLICATIONS: 4.1. Alzheimer¡¯s Disease; 4.2. Parkinson¡¯s Disease; 4.3. Unipolar Depression; 4.4 Bipolar Disorder; 4.5. Schizophrenia
CHAPTER 5 COMMERCIAL POTENTIAL OF SELECTED RESEARCH FINDINGS: 5.1. Alzheimer¡¯s Disease; 5.2. Parkinson¡¯s Disease; 5.3. Unipolar Depression; 5.4. Bipolar Disorder; 5.5. Schizophrenia
CHAPTER 6 EXPERT COMMENTARIES: 6.1. Mark A. Smith, PhD, Professor of Pathology, Case Western Reserve University; 6.2. Maryka Quik, PhD, Professor, The Parkinson¡¯s Institute; 6.3. Ross L. Stein, PhD, Director, Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair; 6.4. Susan L. Stoddard, PhD, Licensing Manager, Mayo Clinic; 6.5. Michael Palfreyman, PhD, DSc, Vice President, Program Management and Drug Development, En Vivo Pharmaceuticals; 6.6. C. Anthony Altar, Ph.D., President and CSO, Psychiatric Genomics; 6.7. Robert G. Urban, PhD, President and CEO, Acretia; 6.8. Pamela Sklar, MD, PhD, Associate Professor of Psychiatry, Harvard Medical School
CHAPTER 7 COMPANY PROFILES: 7.1. Acadia Pharmaceuticals; 7.2. Axonyx; 7.3. Biomind; 7.4. Cortex; 7.5. Cytos Biotechnology; 7.6. Elan; 7.7. En Vivo; 7.8. ExonHit; 7.9. GlaxoSmithKline; 7.10. Lay Line Genomics; 7.11. Memory Pharmaceuticals; 7.12. Merck & Co.; 7.13. Neuro3D; 7.14. Neurochem; 7.15 Nymox; 7.16. Panacea Pharmaceuticals; 7.17. Psychiatric Genomics; 7.18. Roche; 7.19. sanofi-aventis; 7.20. TorreyPines Therapeutics
References
Index
List of Tables and Figures: Table 4.1.Potential Alzheimer¡¯s Disease-Modifying or Preventing Compounds in R&D; Table 4.2.Potential Ion Channel Modulating Compounds in Development for Alzheimer¡¯s Disease; Table 4.3. Compounds in Development for Alzheimer¡¯s Disease, Miscellaneous Mechanisms; Table 4.4. Potential Targets and Target Classes for Alzheimer¡¯s Disease; Table 4.5. Compounds in Development for Parkinson¡¯s Disease; Table 4.6. Potential Targets and Target Classes for Parkinson¡¯s Disease; Table 4.7. Compounds in Development for Unipolar Depression; Table 4.8. Potential Targets and Target Classes for Unipolar Depression; Table 4.9. Compounds in Development for Bipolar Disorder; Table 4.10. Potential Targets and Target Classes for Bipolar Disorder; Table 4.11. Antipsychotic Compounds in Development; Table 4.12. Genes That Have Been Linked to Susceptibility for Schizophrenia; Table 4.13. Potential Targets and Target Classes for Schizophrenia

Abstract

Current therapies for neurodegenerative and psychiatric diseases leave much to be desired. Alzheimer’s and Parkinson’s diseases are an increasing burden on the health care systems of the developed countries as the proportion of their elderly population rises. As for psychiatric disorders, their social and economic impact can be measured by the fact that antipsychotics and antidepressants account for nearly a quarter of total sales for the world’s top 10 best-selling drugs. Potential Breakthroughs in Neurotherapeutics: Alzheimer’s Disease, Parkinson’s Disease, Depression, Bipolar Disorder, and Schizophrenia, a new CHA Advances report, provides a comprehensive assessment of truly innovative, early-stage research that we feel will translate into significant advances in neurotherapy. Specifically, it:

Surveys current basic academic research relevant to drug or target discovery
Highlights topics that show promise of future commercial potential
Examines conditions in the technology transfer milieu relevant to these emerging opportunities
Assesses the commercial potential for these emerging opportunities
Seeks the views of individuals in industry and academia with insight into the foregoing issues

The report begins with an analysis of the technology transfer process that bridges university research and the commercial world ¯ its triumphs, but also its difficulties operating in the current risk-aversive commercial environment. Although industrial R&D activity focused on CNS disorders is intense, progress toward significant innovation remains slow and largely dependent on new leads generated from academia. Potential Breakthroughs in Neurotherapeutics describes one research program in neurology that is turning out to be a ‘poster child’ for translational medicine.

For each of the 5 diseases, Potential Breakthroughs in Neurotherapeutics reviews consensus thinking about the pathophysiological mechanisms, targets, and the state-of-the-art in drug therapy. Then it launches into a review of significant research findings in each disease ¯ the compounds and their targets already in discovery or early development with potential therapeutic value. In evaluating the commercial potential of each target or compound, the report relies on a proprietary scoring system based on the following criteria:

Stage of the project
Number of directly related citations in PubMed
Strength of the mechanistic story and theoretical support
Efficacy probability based on studies in cells, tissues, or animal disease models
Overall rating from 1 (worst) to 10 (best)

More than 125 compounds and more than 40 targets, sponsored by 82 companies, are subjected to this rigorous evaluative process. Moreover, early stage research within each disease area is given an overall rating, and particularly strong compounds, targets, or therapeutic approaches are singled out for discussion. The report supplements this rich analysis with interviews with 8 thought leaders in neurotherapeutics from industry and academia, plus profiles of 20 companies at the forefront of CNS research.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Potential Breakthroughs in Neurotherapeutics: Alzheimer’s Disease, Parkinson’s Disease, Depression, Bipolar Disorder, and Schizophrenia

Table of Contents

Abstract